Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial We derived disease progression and therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results